Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: Powerful eye health application technique and therapeutic platform

Drug Testing and Analysis

Volumn 4, Issue 6, 2012, Pages 468-485

  Babizhayev, Mark A ^a  

^a Innovative Vision Products Incorporated   (United States)

Author keywords

Age related ophthalmic diseases; Human biology; Hydrazide carnosine derivatives; N acetylcarnosine eye drops; Natural medicine; Prodrug formulations

Indexed keywords

ACETYLATION; ALDEHYDES; BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; DISEASE CONTROL; DROPS; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPHTHALMOLOGY; PEPTIDES; TARGETED DRUG DELIVERY;

AGE-RELATED; AGE-RELATED OPHTHALMIC DISEASE; CARNOSINE; EYE DROPS; HUMAN BIOLOGY; HYDRAZIDE CARNOSINE DERIVATIVE; N-ACETYLCARNOSINE EYE DROP; NATURAL MEDICINE; PRODRUG FORMULATION; PRODRUGS;

ANTIOXIDANTS;

ALDEHYDE DERIVATIVE; CARBOHYDRATE DERIVATIVE; CARNOSINE; DIPEPTIDE L CARNOSINE; EYE DROPS; HYDRAZIDE DERIVATIVE; HYSTIDYLHYDRAZIDE; N ACETYLCARNOSINE; PLACEBO; PRODRUG; SCHIFF BASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATARACT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG PURIFICATION; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; EYE DISEASE; EYE PHOTOGRAPHY; FEMALE; GLYCATION; HALOMETER DISABILITY GLARE TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPEREMIA; LIPID MEMBRANE; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MUCOADHESION; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; RETROILLUMINATION PHOTOGRAPHY; SLIT IMAGE; SPECTROPHOTOMETRY; SYSTEMIC DISEASE; VISUAL ACUITY;

EID: 84861664708     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.265     Document Type: Article

References (68)

1. W. Gulewitsch, S. Amiradzibi. Uber das Carnosin eine neue organische base des fleischextraktes. Berichte der Deutschen Chemischen Gesellschaft 1900, 33, 1902.
2. K. G. Crush. Carnosine and related substances in animal tissues. Comp. Biochem. Phys. 1970, 34, 3.
3. S. M. Green, F. L. Margolis, M. Grillo, H. Fisher. Enhanced carnosine (β-alanyl-L-histidine) breakdown and histamine metabolism following treatment with compound 48/80. Eur. J. Pharmacol. 1984, 99, 79.
4. A. A. Boldyrev, S. E. Severin. The histidine-containing dipeptide carnosine and anserine: distribution properties and biological significance. Adv. Enzyme Regul. 1990, 30, 175.
5. F. Margolis. Carnosine in the primary olfactory pathway. Science 1974, 184, 909.
6. A. A. Boldyrev, A. M. Dupin, A. Ya. Bunin, M. A. Babizhayev, S. E. Severin. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem. Int. 1987, 15, 1105.
7. J. L. Jay, D. J. Miller, J. D. Morrison, J. J. O'Dowd. Histidyl derivatives in rabbit lens and their diminution in human cataract. Meeting Abstracts. The Journal of Physiology London 1990, 420, 155.
8. J. J. O'Dowd, D. J. Robins, D. J. Miller. Detection, characterization and quantification of carnosine and other histidyl derivatives in cardiac and skeletal muscle. Biochim. Biophys. Acta 1988, 967, 241.
9. P. R. Carnegie, M. Z. Ilic, M. O. Etheridge, M. G. Collins. Improved high-performance liquid chromatographic method for analysis of histidine dipeptides anserine, carnosine and balenine present in fresh meat. J. Chromatogr. 1983, 261, 153.
10. L. Flancbaum, D. N. Brotman, J. C. Fitzpatrick, T. Van Es, E. Kasziba, H. Fisher. Existence of carcinine, a histamine-related compound, in mammalian tissues. Life Sci. 1990, 47, 1587.
11. M. A. Babizhayev, M.-C. Seguin, J. Gueyne, R. P. Evstigneeva, E. A. Ageyeva, G. A. Zheltukhina. L-Carnosine (β-alanyl-L-histidine) and carcinine (β -alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid peroxidase activities. Biochem. J. 1994, 304, 509.
12. D. Yorston. Cataract complications. Community Eye Health Journal 2008, 21, 1.
13. C. Kupfer, B. Underwood, T. Gillen, Leading causes of visual impairment worldwide. In Principles and Practice of Ophthalmology. Basic Sciences, (Eds: D. M. Albert, F. A. Jakobiec), W. B. Saunders & Co: Philadelphia, 1994, pp. 1249-1255.
14. M. A. Babizhayev, A. I. Deyev, L. F. Linberg. Lipid peroxidation as a possible cause of cataract. Mech. Ageing Dev. 1988, 44(1), 69.
15. M. A. Babizhayev, A. I. Deyev, V. N. Yermakova, I. V. Brikman, J. Bours. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drug Res. Dev. 2004, 5(3), 125.
16. M. A. Babizhayev, A. I. Deyev. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim. Biophys. Acta 1989, 1004(1), 124.
17. M. A. Babizhayev, A. I. Deyev. Free radical oxidation of lipids and thiol groups in the formation of a cataract. Biofizika 1986, 31(1), 109.
18. A. Guiotto, P. Ruzza, M. A. Babizhayev, A. Calderan. Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg. Med. Chem. 2007, 15(18), 6158.
19. M. A. Babizhayev. Method for Topical Treatment of Eye Disease and Composition and Device for said Treatment. Patent No. WO 2004/028536 A1. 2004.
20. M. A. Babizhayev, K. Meguro. Combined use of carnosinase Inhibitor with L-Carnosines and Composition. Patent No. WO 2004/064866 PCT/JP2004/000351. 2004.
21. M. A. Babizhayev, V. N. Yermakova, N. L. Sakina, R. P. Rozhkova, G. A. Zheltukhina. N-acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clin. Chim. Acta 1996, 254, 1.
22. M. A. Babizhayev. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim. Biophys. Acta 1989, 1004, 363.
23. M. A. Babizhayev, E. Bozzo Costa. Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochim. Biophys. Acta 1994, 1225, 326.
24. M. A. Babizhayev, Y. E. Yegorov. Advanced drug delivery of N-acetylcarnosine (N-acetyl-beta-alanyl-L-histidine), carcinine (beta-alanylhistamine) and L-carnosine (beta-alanyl-L-histidine) in targeting peptide compounds as pharmacological chaperones for use in tissue engineering, human disease management and therapy: from in vitro to the clinic. Recent Pat. Drug. Deliv. Formul. 2010, 4(3), 198.
25. B. S. Szwergold. Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem. Biophys. Res. Commun. 2005, 336(1), 36.
26. M. A. Babizhayev, A. I. Deyev, V. N. Yermakova, N. G. Davydova, N. I. Kurysheva, V. S. Doroshenko, et al. Image analysis and glare sensitivity in human age-related cataracts. Clin. Exp. Optom. 2003, 86(3), 157.
27. M. A. Babizhayev, A. I. Deyev, V. N. Yermakova, Y. A. Semiletov, N. G. Davydova, V. S. Doroshenko, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R. D. 2002, 3(2), 87.
28. M. A. Babizhayev, A. I. Deyev, V. N. Yermakova, Yu A. Semiletov, N. G. Davydova, N. I. Kurysheva, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001, 22, 979.
29. M. A. Babizhayev, V. N. Yermakova, A. I. Deyev, M.-C. Seguin. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. Journal of Anti-Aging Medicine 2000, 3, 43.
30. M. A. Babizhayev. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res. 2004, 7, 186.
31. M. A. Babizhayev, V. N. Yermakova, Y. A. Semiletov, A. I. Deyev. The natural histidine-containing dipeptide N-acetylcarnosine as an antioxidant for ophthalmic use. Biochemistry (Moscow) 2000, 65, 588.
32. F. L. Ferris 3rd, A. Kassoff, G. H. Bresnick, I. Bailey. New visual acuity charts for clinical research. Am. J. Ophthalmol. 1982, 94, 91.
33. F. L. Ferris, R. D. Sperduto. Standardized illumination for visual acuity testing in clinical research. Am. J. Ophthalmol. 1982, 94, 97.
34. M. A. Babizhayev. Glare disability and driving safety. Ophthalmic Res. 2003, 35(1), 19.
35. M. A. Babizhayev, M.-C. Seguin. Process of Assessment of Ocular Dysfunctions and Implementation Devices of this Process. US Patent No. 6, 007, 203. 1999.
36. M. A. Babizhayev, E. Bozzo Costa. Composizioni Farmaceutiche Contenenti N-acetilcarnosina per il Trattamento della Cataratta. Italian Patent No. A61K gruppo 37/00 20122 MI, 1993.
37. M. A. Babizhayev, E. Bozzo Costa. Pharmaceutical Compositions Containing N-acetylcarnosine for the Treatment of Cataract. Patent No. PCT/EP 94/03340 SCB 238 PCT, 1994.
38. M. A. Babizhayev. Method for Topical Treatment of Eye Disease and Composition and Device for said Treatment. US Patent No. US 7, 795, 203 B2, 2010, PCT No. PCT/IB03/04259, 2003.
39. M. A. Babizhayev, A. I. Deyev, V. N. Yermakova, V. V. Remenschikov, J. Bours. Revival of the lens transparency with N-acetylcarnosine. Curr. Drug Ther. 2006, 1, 91.
40. M. A. Babizhayev. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J. Pharmacol. Toxicol. 2006, 1(3), 201.
41. M. A. Babizhayev. Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Biochim. Biophys. Acta 1996, 1315, 87.
42. C. Owsley, B. T. Stalvey, J. Wells, M. E. Sloane, G. McGwin Jr. Visual risk factors for crash involvement in older drivers with cataract. Arch. Ophthalmol. 2001, 119, 881.
43. N. H. Ansari, L. Wang, S. K. Srivastava. Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract. Biochem. Mol. Med. 1996, 58(1), 25.
44. H. Ukeda, Y. Hasegawa, Y Harada, M. Sawamura. Effect of carnosine and related compounds on the inactivation of human Cu, Zn-superoxide dismutase by modification of fructose and glycolaldehyde. Biosci. Biotech. Bioch. 2002, 66(1), 36.
45. J. H. Kang, K. S. Kim, S. Y. Choi, H. Y. Kwon, M. H. Won, T. C. Kang. Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu, Zn-superoxide dismutase modification. Biochim. Biophys. Acta 2002, 1570, 89.
46. G. Aldini, M. Carini, G. Beretta, S. Bradamante, R. M. Facino. Carnosine is a quencher of 4-hydroxy-nonenal: through what mechanism of reaction? Biochem. Biophys. Res. Commun. 2002, 298(5), 699.
47. G. Aldini, P. Granata, M. Carini. Detoxification of cytotoxic alpha, beta-unsaturated aldehydes by carnosine: characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J. Mass Spectrom. 2002, 37(12), 1219.
48. A. R. Hipkiss, J. E. Preston, D. T. Himswoth, V. C. Worthington, N. J. Abbot. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci. Lett. 1997, 238(3), 135.
49. A. R. Hipkiss, V. C. Worthington, D. T. Himsworth, W. Herwig. Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim. Biophys. Acta 1998, 1380(1), 46.
50. S. Zhou, E. A. Decker. Ability of carnosine and other skeletal muscle components to quench unsaturated aldehydic lipid oxidation products. J. Agric. Food Chem. 1999, 47(1), 51.
51. L. J. Hobart, I. Seibel, G. S. Yeargans, N. W. Seidler. Anti-crosslinking properties of carnosine: Significance of histidine. Life Sci 2004, 75, 1379.
52. C. Brownson, A. R. Hipkiss. Carnosine reacts with a glycated protein. Free Radical Biol. Med. 2000, 28(10), 1564.
53. A. R. Hipkiss, H. Chana. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem. Biophys. Res. Commun. 1998, 248(1), 28.
54. A. R. Hipkiss, J. Michaelis, P. Syrris. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS Lett. 1995, 371(1), 81.
55. A. R. Hipkiss, J. Michaelis, P. Syrris, S. Kumar, Y. Lam. Carnosine protects proteins against in vitro glycation and cross-linking. Biochem. Soc. Trans. 1994, 22(4), 399S.
56. A. R. Hipkiss. Glycation, ageing and carnosine: are carnivorous diets beneficial? Mech. Ageing Dev. 2005, 126(10), 1034.
57. N. H. Ansari, L. Wang, A. A. Erwin, D. F. Church. Glucose-dependent formation of free radical species in lens homogenate. Biochem. Mol. Med. 1996, 59(1), 68.
58. N. W. Seidler, G. S. Yeargans, T. G. Morgan. Carnosine disaggregates glycated alpha-crystallin: an in vitro study. Arch. Biochem. Biophys. 2004, 427, 110.
59. D. I. Price, P. M. Rhett, S. R. Thorpe, J. W. Baynes. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 2001, 276, 48967.
60. S.-I. Yamagishi, K. Nakamura, T. Imaizumi. Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Review 2005, 1, 93.
61. K. O. Muranov, A. K. Dizhevskaia, A. A. Boldyrev, O. E. Karpova, N. L. Sheremet, G. S. Polunin, et al. Search for chaperon-like anticataract drugs, the antiaggregants of lens crystallins. Communication. 1. Chaperon-like activity of N-acetyl carnosine dipeptide: in vitro study on a model of ultraviolet-induced aggregation of betaL-crystallin. Vestn. Oftalmol. 2008, 124(2), 3.
62. A. R. Hipkiss, C. Brownson, M. F. Bertani, E. Ruiz, A. Ferro. Reaction of carnosine with aged proteins: another protective process? Ann. N. Y. Acad. Sci. 2002, 959, 285.
63. M. A. Babizhayev. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev. Ind. Pharm. 2008, 34(10), 1071.
64. Z. Tianyang, Z. Ling, W. Liya, Z. Junjie. Ocular pharmacokinetics of carnosine 5% eye drops following topical application in rabbit. J. Ocul Pharmacol Ther. 2010, Jan 19. [Epub ahead of print].
65. J. W. Ha, A. B. Schwahn, K. M. Downard. Ability of N-acetylcarnosine to protect lens crystallins from oxidation and oxidetive damage by radical probe mass spectrometry (RP-MS). Rapid. Commun. Mass Spectrom. 2010, 24(19), 2900.
66. M. A. Babizhayev, M.-C. Seguin. Pseudodipeptide Product Having an Imidazole Grouping and Applications. Patent No. WO 95/12581. PCT/FR94/01272. 1994.
67. M. A. Babizhayev, M.-C. Seguin. Coupling Product Obtained from Histamine and an Amino Acid. Patent No. WO 94/19325. PCT/FR94/00189. 1994.
68. M. A. Babizhayev, Y. Courbebaisse, J.-F. Nicolay, Yu A. Semiletov. Design and biological activity of imidazole-containing peptidomimetics with a broad-spectrum antioxidant activity. Lett. Pept. Sci. 1998, 5, 163.